Benjamin Blyth

Dr. Benjamin Blyth

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Radiation Research
Verified
Journal Article
Closed access
PDF file
BBBenjamin Blyth
Benjamin Blyth
PSPamela J. Sykes
Pamela J. Sykes
The term radiation-induced bystander effect is used to describe radiation-induced biological changes that manifest in unirradiated cells remaining within an irradiated cell population. Despite their failure to fit into the framework of classical radiobiology, radiation-induced bystander effects have entered the mainstream and have become established in the radiobiology vocabulary as a bona fide radiation response. However, there is still no consensus on a precise definition of radiation-induced bystander effects, which currently encompasses a number of distinct signal-mediated effects. These effects are classified here into three classes: bystander effects, abscopal effects and cohort effects. In this review, the data have been evaluated to define, where possible, various features specific to radiation-induced bystander effects, including their timing, range, potency and dependence on dose, dose rate, radiation quality and cell type. The weight of evidence supporting these defining features is discussed in the context of bystander experimental systems that closely replicate realistic human exposure scenarios. Whether the manifestation of bystander effects in vivo is intrinsically limited to particular radiation exposure scenarios is considered. The conditions under which radiation-induced bystander effects are induced in vivo will ultimately determine their impact on radiation-induced carcinogenic risk.

7 August 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AGAndrew A. Guirguis
Andrew A. Guirguis
YOYaara Ofir-Rosenfeld
Yaara Ofir-Rosenfeld
KKKathy Knezevic
Kathy Knezevic
WBWesley Blackaby
Wesley Blackaby
DHDavid Hardick
David Hardick
MDMark A. Dawson
Mark A. Dawson
Therapies that enhance antitumor immunity have altered the natural history of many cancers. Consequently, leveraging nonoverlapping mechanisms to increase immunogenicity of cancer cells remains a priority. Using a novel enzymatic inhibitor of the RNA methyl­transferase METTL3, we demonstrate a global decrease in N6-methyladenosine (m6A) results in double-stranded RNA (dsRNA) formation and a profound cell-intrinsic interferon response. Through unbiased CRISPR screens, we establish dsRNA-sensing and interferon signaling are primary mediators that potentiate T-cell killing of cancer cells following METTL3 inhibition. We show in a range of immunocompetent mouse models that although METTL3 inhibition is equally efficacious to anti–PD-1 therapy, the combination has far greater preclinical activity. Using SPLINTR barcoding, we demonstrate that anti–PD-1 therapy and METTL3 inhibition target distinct malignant clones, and the combination of these therapies overcomes clones insensitive to the single agents. These data provide the mole­cular and preclinical rationale for employing METTL3 inhibitors to promote antitumor immunity in the clinic. Significance: This work demonstrates that METTL3 inhibition stimulates a cell-intrinsic interferon response through dsRNA formation. This immunomodulatory mechanism is distinct from current immunotherapeutic agents and provides the molecular rationale for combination with anti–PD-1 immune-checkpoint blockade to augment antitumor immunity. This article is featured in Selected Articles from This Issue, p. 2109

20 November 2017 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
BBBenjamin Blyth
Benjamin Blyth
ACAidan J. Cole
Aidan J. Cole
MMMichael MacManus
Michael MacManus
OMOlga A. Martin
Olga A. Martin

27 October 2017 in Cancers
Verified
Journal Article
Open access
PDF file
MHMohammad Habash
Mohammad Habash
LBLuis C. Bohorquez
Luis C. Bohorquez
EKElizabeth Kyriakou
Elizabeth Kyriakou
Tomas KronTomas Kron
Tomas Kron
OMOlga Martin
Olga Martin
BBBenjamin Blyth
Benjamin Blyth
Whilst the near instantaneous physical interaction of radiation energy with living cells leaves little opportunity for inter-individual variation in the initial yield of DNA damage, all the downstream processes in how damage is recognized, repaired or resolved and therefore the ultimate fate of cells can vary across the population. In the clinic, this variability is observed most readily as rare extreme sensitivity to radiotherapy with acute and late tissue toxic reactions. Though some radiosensitivity can be anticipated in individuals with known genetic predispositions manifest through recognizable phenotypes and clinical presentations, others exhibit unexpected radiosensitivity which nevertheless has an underlying genetic cause. Currently, functional assays for cellular radiosensitivity represent a strategy to identify patients with potential radiosensitivity before radiotherapy begins, without needing to discover or evaluate the impact of the precise genetic determinants. Yet, some of the genes responsible for extreme radiosensitivity would also be expected to confer susceptibility to radiation-induced cancer, which can be considered another late adverse event associated with radiotherapy. Here, the utility of functional assays of radiosensitivity for identifying individuals susceptible to radiotherapy-induced second cancer is discussed, considering both the common mechanisms and important differences between stochastic radiation carcinogenesis and the range of deterministic acute and late toxic effects of radiotherapy.

13 March 2015 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
SHShino Homma‐Takeda
Shino Homma‐Takeda
KKKeisuke Kitahara
Keisuke Kitahara
KSKyoko Suzuki
Kyoko Suzuki
BBBenjamin Blyth
Benjamin Blyth
NSNoriyoshi Suya
Noriyoshi Suya
YSYoshiya Shimada
Yoshiya Shimada

1 December 2006 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
GZGuoxin Zeng
Guoxin Zeng
TDTanya K. Day
Tanya K. Day
AHAntony M. Hooker
Antony M. Hooker
BBBenjamin Blyth
Benjamin Blyth
MBMadhava Bhat
Madhava Bhat
PSPamela J. Sykes
Pamela J. Sykes